Wellbutrin buyers continued to urge the Third Circuit Monday to overturn a decision nixing their pay-for-delay suit against GlaxoSmithKline PLC over its popular antidepressant drugs, saying the appeals court’s recent precedential ruling in a product liability case over the drug Fosamax further supports their arguments.

In a letter submitted Monday, Wellbutrin buyers told the appeals court that its March 22 precedential decision in In Re. Fosamax Product Liability Litigation that held that a jury should decide hypothetical questions of law, and not the court, applies to multiple questions put forward in their suit against GSK.

GSK is represented by Stephen J. Kastenberg, Jessica M. Anthony, Leslie E. John, Jason A. Leckerman and Edward D. Rogers of Ballard Spahr LLP.

Read the full article here. Subscription may be required.